Subo

Medical Oncologist Cancer genomics Precision Oncology

[Omico Australia @OmicoAustralia]

Our Superstar @Subo81495328 gave a great argument supporting that precision medicine is NOT past its use by date NECTA drug development meeting’s debate today!

[Frank Lin @fpylin]

#cholangiocarcinoma: better real-world outcomes are seen in patients who received genomic matched drugs in the MoST study. Time to treat CCa like lung ca. Trials/drug access must improve. #AGITG22 @Subo81495328 #Precision @OmicoAustralia @TrialsCentre

[Thoracic Oncology Group of Australasia @TOGAANZ]

#ASPiRATIONstudy identifies more actionable mutations than standard of care testing & is optimal workup strategy for Aus newly diag non-sq mNSCLC patients https://t.co/rxH89p0ogC Refer from any site https://t.co/QoR1rxFYE6 @OmicoAustralia @TrialsCentre #LCSM

[Professor DM Thomas @ProfDMThomas]

No. 4 pan-cancer approvals: a game-changer for up to 10% of all cancer patients, esp. rare and less common. FDA Approves Pembrolizumab for TMB-High Tumors https://t.co/0iggdQnESd via @onclive @OmicoAustralia @RareCancers @kinghorncancer @GarvanInstitute

[Omico Australia @OmicoAustralia]

#MoST Our brilliant bio- and clinical informaticians: Frank Lin, John Grady and Subo Thavaneswaran! Working on matching the right patients to the right trials around the country. 13,000 lines of code and counting...@GarvanInstitute @RareCancers

[Subo @Subo81495328]

@OmicoAustralia Great work team!👍